Key Insights

Highlights

Success Rate

89% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

7.7%

1 terminated out of 13 trials

Success Rate

88.9%

+2.4% vs benchmark

Late-Stage Pipeline

15%

2 trials in Phase 3/4

Results Transparency

25%

2 of 8 completed with results

Key Signals

2 with results89% success

Data Visualizations

Phase Distribution

11Total
Not Applicable (5)
Early P 1 (1)
P 1 (1)
P 2 (2)
P 3 (1)
P 4 (1)

Trial Status

Completed8
Not Yet Recruiting3
Terminated1
Recruiting1

Trial Success Rate

88.9%

Benchmark: 86.5%

Based on 8 completed trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT07531966RecruitingPrimary

Vascular Complications After Kidney Transplantation

NCT07488481Early Phase 1Not Yet Recruiting

Renal Ex Vivo SYN002 Perfusion to Eliminate CMV Transmission

NCT05220397Phase 3TerminatedPrimary

Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients

NCT06913023Phase 2Not Yet RecruitingPrimary

Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus

NCT06858098Not ApplicableNot Yet Recruiting

Outcomes of a Pre-operative Exercise Programme for Live Donor and Recipient Kidney Transplant Patients

NCT05975450Phase 1CompletedPrimary

Subcutaneous Abatacept in Renal Transplant Recipients

NCT06011850CompletedPrimary

Investigation of the Effects of Quadratus Lumborum Block Applied to Patients in Kidney Transplant Surgery

NCT03697317Not ApplicableCompletedPrimary

Televideo Exercise and Nutrition Program for Kidney Transplant Recipients

NCT01753505Not ApplicableCompletedPrimary

Clinical Significance of 64-slice Multidetector Coronary CT Angiography to Evaluate the Prevalence and Severity of Coronary Artery Disease in Renal Transplant Recipients

NCT00189150Phase 4CompletedPrimary

Pharmacokinetics of Mmf and Valganciclovir

NCT00307125Phase 2Completed

Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies

NCT01087190Not ApplicableCompletedPrimary

Isoniazid (INH) Treatment Based on ELISPOT Assay

NCT01093703Not ApplicableCompleted

Chronotherapy Versus Conventional BP Control to Correct Abnormal Circadian BP Pattern in Kidney Transplant Recipients

Showing all 13 trials

Research Network

Activity Timeline